Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| CA3942 | CA9446 | U.S. | 1998 | HIV1 | B | Plasma | None |
Treatment History
| Order | Regimen | Weeks |
| 1 | DDI | 42 |
| 2 | DDC | 45 |
| 3 | D4T | 21 |
| 4 | 3TC+D4T+ SQV | 34 |
| 5 | 3TC+D4T+IDV | 105 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| V32I, M46I, I47V, L90M | I13V, E35D, N37S, I62V, L63P, I93L, C95F |
| >CA9446| codons 1-99 PQITLWQRPLVTVKIGGQLKEALLDTGADDTILEDMSLPGRWKPKIVGGIGGFIKVRQYD QVPIEICGHKAIGTVLVGPTPVNIIGRNLMTQLGFTLNF |
RT Sequence
| NRTIMajorDRMs | NRTIMinorDRMs | NNRTIMajorDRMs | NNRTIMinorDRMs | Polys | UnusualMuts |
| D67N, K70R, M184V | K219Q | V60I, I135L, T200A, R211K, L283I, E297K, I329L, Q334E, K390R, A400T, Q464QR, S468P, A554S |
| >CA9159| codons 1-560 PISPIETVPVKLKPGMDGPKVKQWPLTEEKIKALVEICTEMEKEGKISKIGPENPYNTPI FAIKKKNSTRWRKLVDFRELNKRTQDFWEVQLGIPHPAGLKKKKSVTVLDVGDAYFSVPL DKDFRKYTAFTIPSLNNETPGIRYQYNVLPQGWKGSPAIFQSSMTKILEPFRKQNPDIVI YQYVDDLYVGSDLEIGQHRAKIEELRQHLLKWGFTTPDQKHQKEPPFLWMGYELHPDKWT VQPIVLPEKDSWTVNDIQKLVGKLNWASQIYAGIKVKQLCKLIRGTKALTEVIPLTKEAE LELAENREILKEPVHGVYYDPSKDLIAELQKQGEGQWTYQIYQEPFKNLKTGKYARMRGA HTNDVKQLTEAVQKIATESIVIWGKTPKFRLPIQKETWETWWTEYWQATWIPEWEFVNTP PLVKLWYQLEKEPIVGAETFYVDGAANRETKLGKAGYVTDRGRRKVVPLTDTTNQKTELQ AIHLALQDSGLEVNIVTDSQYALGIIQAQPDKSESELVSQIIEQLIKKEKVYLAWVPAHK GIGGNEQVDKLVSSGIRKVL |
References
| Author | Title | Citation |
| Kantor, R | Evolution of primary protease inhibitor resistance mutations during protease inhibitor salvage therapy. | AAC, 2002 |
| Gonzales, MJ | HIV-1 reverse transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a Northern California clinic-based population. | J Infect Dis, 2001 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |